Carlumab

Carlumab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	915404-94-3
PubChem
DrugBank
ChemSpider	none
KEGG	D09877

Carlumab (alternate identifier CNTO 888<ref name="Pienta 760–768">Pienta, Kenneth J.,

 Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer, 
 Investigational New Drugs, 
 
 Vol. 31(Issue: 3),
 pp. 760–768,
 DOI: 10.1007/s10637-012-9869-8,
 PMID: 22907596,</ref>) is a discontinued human recombinant monoclonal antibody (type IgG1 kappa)<ref name=":0">

Janssen 2014 Compound Information CNT0888(link). '.

</ref> that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1).<ref name=":1">

NCI Drug Dictionary(link). National Cancer Institute.

2011-02-02.

Accessed 2017-03-24.

</ref><ref>Fetterly, Gerald J.,

 Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data, 
 The Journal of Clinical Pharmacology, 
 
 Vol. 53(Issue: 10),
 pp. 1020–1027,
 DOI: 10.1002/jcph.140,
 PMID: 23878055,</ref><ref>Obmolova, Galina, 
 Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888, 
 Molecular Immunology, 
 
 Vol. 51(Issue: 2),
 pp. 227–233,
 DOI: 10.1016/j.molimm.2012.03.022,
 PMID: 22487721,</ref> Carlumab was under development for use in the treatment of oncology and immune indications<ref>

Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab(link). {{{website}}}. American Medical Association.

</ref><ref> World Health Organization,

 Proposed International Nonproprietary Names: List 104 Full text, 
 , 
 World Health Organization, 
 2010, 
 Geneva, 
  
 Accessed on: 17 August 2015.

</ref> and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes.<ref name=":0" />

The inhibitory binding of Carlumab to CCL2 was hypothesized to inhibit angiogenesis and consequently modulate tumor cell proliferation.<ref name=":1" /><ref name=":0" /> Studies focusing on the effects of Carlumab have been performed in vitro on cell lines and in vivo on mice and in humans including phase 1 and phase 2 clinical trials evaluating the efficacy, safety and dose requirements of the drug. Clinical trials for Carlumab include studies of idiopathic pulmonary fibrosis,<ref>,

 www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A3376, 
  
 American Thoracic Society, 
  
 Series: American Thoracic Society International Conference Abstracts, 
  
  
 DOI: 10.1164/ajrccm-conference.2013.187.1_meetingabstracts.a3376, 
  
  
 Pages: A3376,</ref><ref>

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF) - Full Text View - ClinicalTrials.gov(link). clinicaltrials.gov.

Accessed 2017-03-24.

</ref> castration-resistant metastatic prostate cancer<ref name="Pienta 760–768"/><ref>

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer - Full Text View - ClinicalTrials.gov(link). clinicaltrials.gov.

Accessed 2017-03-24.

</ref> and solid tumors.<ref>Sandhu, Shahneen K.,

 A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors, 
 Cancer Chemotherapy and Pharmacology, 
 
 Vol. 71(Issue: 4),
 pp. 1041–1050,
 DOI: 10.1007/s00280-013-2099-8,
 PMID: 23385782,</ref><ref>

First Study of the Safety of CNTO 888 in Patients With Solid Tumors - Full Text View - ClinicalTrials.gov(link). clinicaltrials.gov.

Accessed 2017-03-24.

</ref>

Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012<ref>

Research and Development | MorphoSys 2012(link). reports.morphosys.com.

Accessed 2017-03-24.

</ref> due to limited success in clinical trials.

References

<references/>

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a medical stub. You can help WikiMD by expanding it!